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Identification of V6.51L 
as a selectivity hotspot 
in stereoselective  A2B adenosine 
receptor antagonist recognition
Xuesong Wang1,6, Willem Jespers1,2,6, Rubén Prieto‑Díaz3,4,6, Maria Majellaro3,4, 
Adriaan P. IJzerman1, Gerard J. P. van Westen1, Eddy Sotelo3,4*, Laura H. Heitman2,5* & 
Hugo Gutiérrez‑de‑Terán2*
The four adenosine receptors (ARs)  A1AR,  A2AAR,  A2BAR, and  A3AR are G protein‑coupled receptors 
(GPCRs) for which an exceptional amount of experimental and structural data is available. Still, limited 
success has been achieved in getting new chemical modulators on the market. As such, there is a clear 
interest in the design of novel selective chemical entities for this family of receptors. In this work, we 
investigate the selective recognition of ISAM‑140, a recently reported  A2BAR reference antagonist. A 
combination of semipreparative chiral HPLC, circular dichroism and X‑ray crystallography was used 
to separate and unequivocally assign the configuration of each enantiomer. Subsequently affinity 
evaluation for both  A2A and  A2B receptors demonstrate the stereospecific and selective recognition 
of (S)‑ISAM140 to the  A2BAR. The molecular modeling suggested that the structural determinants of 
this selectivity profile would be residue  V2506.51 in  A2BAR, which is a leucine in all other ARs including 
the closely related  A2AAR. This was herein confirmed by radioligand binding assays and rigorous free 
energy perturbation (FEP) calculations performed on the  L249V6.51 mutant  A2AAR receptor. Taken 
together, this study provides further insights in the binding mode of these  A2BAR antagonists, paving 
the way for future ligand optimization.
Adenosine receptors (ARs) are a family of G protein-coupled receptors (GPCR) for which an exceptional amount 
of structural and experimental data is  available1,2. Still, the number of therapeutic agents on the market that 
specifically target this family of receptors remains relatively  low3. On the other hand, selective targeting of any 
of the four adenosine receptor subtypes  (A1,  A2A.  A2B and  A3) provides an interesting avenue to address not only 
unmet therapeutic  needs4 and limited off-target  effects5, but also to help elucidating the (patho)physiological 
role of the different receptors within the family. One topic that is receiving increasing interest is the molecular 
mechanisms by which the two  A2AR subtypes regulate the immune response to tumor growth and  metastasis6.
Over the last years, different AR ligands have been developed with optimized selectivity  profiles7–9. Within 
these AR ligand design programs, the generation of potent and selective antagonists has allowed the identifica-
tion of powerful chemical tools to characterize each of the members of this receptor family. Examples include 
the  A2AAR selective antagonist ZM241385, and the  A2BAR selective antagonist ISAM-140, the latter originat-
ing from our in-house optimization program (Fig. 1)7,9–11. The development of ISAM-140 was done follow-
ing careful structure-affinity relationship (SAR) modeling, based on a computational binding mode of this 
chemotype, which suggested an important role of the stereogenic center in the heterocyclic scaffold in its high 
binding affinity (Fig. 1)11,12. The prediction of the active stereoisomer for this chemotype was later confirmed 
indirectly by experimental characterization of the active stereoisomers for representative compounds of a series 
of  cyanopyrimidines10, fluorinated tricyclic  derivatives13 and aza-bioisosteres of the pentagonal  heterocycle14. 
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This binding model proposed that the stereospecific complementarity to the  A2BAR cavity was due to the optimal 
accommodation of the thiophene/furan ring around the chiral center of the core scaffold (Fig. 1), with the  A2BAR 
specific residue  V2506.51 (Ballesteros Weinstein numbering in superscripts)15. Indeed, this valine is replaced by 
a leucine in all other AR subtypes, which could explain the highly selective profile of these series of non-planar 
antagonists towards the  A2BAR.
In this work, we report the chiral separation of ISAM140 and confirm its stereospecific binding mode to 
the  A2BAR. An  A2AAR construct was designed to include the corresponding  A2BAR valine sidechain  (L249V6.51 
 A2AAR mutant), which in line with the starting hypothesis partially recovered the affinity for ISAM-140. Inter-
estingly, this effect was observed for both stereoisomers of the antagonist, and is herein explained on the basis 
of structure-energetic modeling via rigorous free energy perturbation (FEP) calculations. These results validate 
the proposed role of  V2506.51 in the  A2BAR subtype selectivity of these stereospecific chemotype, and paves the 
road for further design of selective antagonists as well as dual  A2AR ligands.
Results
Generating  A2AAR‑ligand models. The binding mode of (S)-ISAM-140 was obtained by superposition 
of the previously published complex of this molecule with our  A2BAR homology-based  model11 onto a modeled 
 L249V6.51  A2AAR mutant, i.e. introducing the  A2BAR sidechain in this position. Such a construct was built and 
equilibrated on the basis of the high-resolution crystal structure of the ZM241385 —  A2AAR complex (see “Meth-
ods”)16. The binding mode obtained included the two key interactions typical of ARs antagonists: (i) hydrogen 
bond(s) with  N2536.55 and (ii) π–π stacking with  F168EL2, both residues completely conserved among  ARs1. The 
high-affinity  A2AAR antagonist ZM241385 showed an optimal shape complementarity with the  A2AAR WT resi-
due  L2496.51 (Fig. 2A), whereas the corresponding  L249V6.51 mutant is expected to minimally disrupt this shape 
complementarity due to a reduced volume (Fig. 2B). On the other hand, the obtained binding modes for (S)-
ISAM-140 on the WT  A2AAR (also obtained assuming the same binding mode as in the  A2BAR homology-based 
 model11) showed a non-optimal fit, in accordance with the lack of affinity exhibited for the  A2AAR receptor by 
this derivative and other compounds within the  series8–11. In particular, the presence of the native  L2496.51 in the 
 A2AAR appeared to introduce a steric clash with either the 2-furyl or 3-thienyl substituents of the ligands, which 
we hypothesized would reduce binding affinities (Fig. 2C). Conversely, introducing the  A2BAR sidechain on the 
modeled  L249V6.51  A2AAR mutant provided a better shape complementarity (Fig. 2D), allowing us to hypoth-
esize that the binding affinity of these antagonists might be recovered to some extent.
Chiral separation of ISAM‑140. The racemic mixture of ISAM-140, obtained as previously  described11, 
was resolved into its enantiopure forms. A combination of chiral HPLC, circular dichroism (CD) spectroscopy 
and X-ray crystallography was employed to separate and unequivocally assign the configuration of the het-
erocyclic stereocenter in each stereoisomer. Semipreparative HPLC separation of ( ±) ISAM-140 on a chiral 
stationary phase (see “Experimental information”) provided the expected enantiomers (Fig. 3) with excellent 
stereochemical purity (> 97%), the analytical and spectroscopy data provided in the Supplementary Informa-
tion. As described previously for 3,4-dihydropyrimidin-2-ones17–19, the characteristic CD activity of the enamide 
chromophore (300–350 nm) allowed the unambiguous assignment of the absolute configuration of each enan-
tiomer (Fig. 3) by comparison with the reported CD data for enantiopure 3,4-dihydropyrimidin-2(1H)-ones of 
known configuration. In the structures shown in Fig. 3, enantiomers that show a negative Cotton effect (blue 
line) contain the furan ring pointing backwards, which corresponds to (S)-ISAM-140. In contrast, the stereoi-
somers giving a positive Cotton effect (red line) contain the pentagonal heterocycle pointing forward, which 
corresponds to (R)-ISAM-140. Single crystals suitable for X-ray analysis were grown by slow evaporation of 
each enantiomer in ethanol. The structures were solved and the data extracted from X-ray crystallography of 
both monocrystals presented in the Supporting Information (Supplementary Table S1)13. The crystal structures 
of (S)-ISAM-140 and (R)-ISAM-140 (monoclinic, Fig. 3) confirmed the configuration assignment established 
by circular dichroism. The benzimidazole moiety is essentially planar in both enantiomers, while the dihydro-
pyrimidine core adopts a pseudo envelope conformation, with the  C4 atom being lightly displaced by 0.26 Å.
Determination of ligand binding affinities. To further confirm the role of position 6.51 as a receptor 
selectivity hotspot, we attempted to express L249V/A6.51  A2AAR and V250L/A6.51  A2BAR mutant receptors. Whilst 

















Figure 1.  2D representation of the chemical structures of the AR ligands used in this work, i.e. ZM241385, ( ±) 
ISAM-140, (R)-ISAM-140 and (S)-ISAM-140. The chiral center in ISAM-140 is indicated with an asterisk.
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could be expressed using standard (non-viral) transfection methods, and consequently the  A2BAR mutants 
designed had to be excluded from further experimentation. Thereafter, we determined the binding affinity of 
ISAM-140, both as a racemate and pure enantiomers, together with the prototypical antagonist ZM241385 at 
both WT and mutant  A2AARs, as well as at the WT  A2BAR (Fig. 4 and Table 1). The affinities determined for 
ZM241385 and racemic ISAM-140 on WT  A2BAR (pKi of 6.78 and 7.86, respectively, see Table 1) were in line 
with previous  reports10. As expected from the modeling, the corresponding data for the enantiopure forms of 
ISAM-140 showed that the affinity of the racemic mixture was due to (S)-ISAM-140, with even a gain in binding 
affinity as compared to the racemic mixture (∆pKi = 0.19), which was dramatically reduced for the low-affinity 
(R)-ISAM-140 (∆pKi = 1.31 between both enantiomers, Fig. 4A and Table 1).
For the  A2AAR, we first established whether the L249V/A6.51 mutants still sufficiently bound ZM241385, to 
validate the viability of using it as a radioligand in the homologous displacement assays. Of note, the result-
ing  KD values could then be used to obtain  Ki values from the  IC50 values (see Methods), which enabled us to 
compare affinity values for WT and mutant  A2AARs. Moreover, the resulting  Bmax values showed that the  A2AAR 
 L249V6.51 mutant had a lower expression level than the WT  A2AAR. A slight reduction in affinity of both  [3H]
ZM241385 and ZM241385 was observed on this mutant (Table 1), which was in line with our hypothesis that 
the shape complementarity between ZM241385 and L249 is mostly preserved with a smaller Val. However, a 
substantial hydrophobic side chain was important for the binding of this antagonist to the  A2ARs, since its affinity 
to the  A2AAR  L249A6.51 mutant was completely lost (Supplementary Fig. S2), in line with previous  reports20. The 
results of the displacement assays for ISAM-140 (racemate and both stereoisomers) are illustrated in Fig. 4B and 
Table 1. Although one data point for ( ±) ISAM-140 at the concentration of  10−5 M was excluded from the curve 
of WT  A2AAR, due to low water solubility, in all cases the binding affinity for the WT  A2AAR was very low (within 
micromolar range). Notably, it followed the same trend as observed on WT  A2BAR, i.e. the highest affinity for 
(S)-ISAM-140 and the lowest for (R)-ISAM-140. The selectivity ratio between  A2B and  A2A ARs was substantial 
for ( ±) ISAM-140, (∆pKi = 1.33), in line with the previous reports for this  ligand11. This difference was maintained 
for the eutomer (S)-ISAM-140 (∆pKi = 1.29) and, to a lower extent, even for (R)-ISAM-140 (∆pKi = 0.79), which 
is expected due to its already low affinity for  A2BAR. Notably, the affinity values were significantly recovered at 
Figure 2.  Binding mode of two ligands, ZM241385 (in blue, panels A and B) and (S)-ISAM-140 (orange, 
panels C and D), to the WT (panels A and C) and the  L249V6.51 mutant (panels B and D)  A2AAR. Volumetric 
occupancies are shown as surface. Figure created with Pymol v2.0.
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Figure 3.  Chiral HPLC separation, circular dichroism spectra and crystal X-ray structure of compounds (R)-
ISAM-140 and (S)-ISAM-140.
Figure 4.  Displacement of (A) specific  [3H]PSB-603 binding from  A2BAR and (B) specific  [3H]ZM241385 
binding from the WT and the  L249V6.51 mutant  A2AAR at 25 °C by ZM241385 (blue), ( ±) ISAM-140 (yellow), 
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the  A2AAR  L249V6.51 mutant, i.e. when the receptor was more “A2BAR-like”, thus supporting the initial modeling 
hypothesis. The moderate affinity gains observed for the  A2AAR  L249V6.51 mutant as compared to the  A2AAR 
WT [0.39, 0.41 and 0.51 log unit for ( ±) ISAM-140, (S)-ISAM-140, and (R)-ISAM-140, respectively, see Table 1] 
did not restore the affinity values as in the WT  A2BAR.
Computational characterization of binding free energies. Finally, we investigated the observed 
shifts in binding affinities for (S)-ISAM-140, (R)-ISAM-140 and ZM241385 in the context of the structural 
binding model of these molecules to the  A2AAR. The approach was to compare the WT and  L2496.51V mutant 
 (A2B equivalent) versions of  A2AAR using the Q-FEP  protocols21,22. This strategy consists on the simulation of 
the mutation (Leu to Val) both in the presence and absence of each of the docked ligands. While the struc-
ture of the ZM241385 —  A2AAR complex is experimentally  known16, the binding mode of each enantiomer of 
ISAM140 was inferred from our previous work on this  chemotype7. Figure 5 summarizes the calculated shift in 
the free energy of binding due to the  L249V6.51 mutation for each enantiomer of ISAM-140 and for ZM241385. 
It can be observed a very good agreement between the calculations and the experimental affinity data here 
reported in Fig. 4B, with a very low mean average error (MAE = 0.25 kcal/mol, numerical data provided in Sup-
plementary Table S2). Thus, the simulation of this mutation resulted in a predicted increase in affinity (nega-
tive ∆∆Gbind (mut − WT) values in Fig. 5) for both enantiomers of ISAM-140, with values proportional to those 
extracted from the experimental data. Conversely, the experimental affinity of ZM241385 is decreased for the 
 L249V6.51 mutant  A2AAR, which is also captured by our modeling as a mild positive value for the calculated 
∆∆Gbind (mut − WT).
Discussion
In this work, we investigated the role of position 6.51 in determining the specificity for  A2BAR binding of a 
series of chiral antagonists recently developed for this receptor. The modeling hypothesis behind the design of 
the potent antagonist ISAM-140 placed the S-stereoisomer in perfect shape complementarity with  Val2506.51 in 
the  A2BAR, while analogous docking in the high resolution  A2AAR bearing a bulkier Leu in the same position 
showed initial steric clashes. This allowed us to propose this sidechain as a landmark for  A2BAR selectivity for 
this ligand class, and the (S)-ISAM-140 as the active stereoisomer. To experimentally validate this hypothesis, the 
Table 1.  Bmax and  pKD values of  [3H]ZM241385 and binding affinities of ZM241385, ( ±) ISAM-140, 
(R)-ISAM-140 and (S)-ISAM-140 on WT  A2BAR, WT and  L249V6.51 mutant  A2AARs. Data is presented 
as mean ± SEM of three individual experiments, each performed in duplicate.  pKD values obtained from 
homologous competition displacement assays on transiently transfected HEK293-hA2AAR membranes at 
25 °C.  pKi values obtained from displacement assays of specific  [3H]PSB-603 binding from CHO-spap-hA2BAR 
membrane or specific  [3H]ZM241385 binding from transiently transfected WT and mutant HEK293-hA2AAR 
membranes at 25 °C.
Receptor
Bmax (pmol/mg)a pKD a pKib
[3H]ZM241385 ZM241385 ( ±) ISAM-140 (R)-ISAM-140 (S)-ISAM-140
A2BAR (WT) – – 6.78 ± 0.06 7.86 ± 0.09 6.74 ± 0.09 8.05 ± 0.06
A2AAR (WT) 3.92 ± 0.23 8.59 ± 0.09 8.62 ± 0.04 6.53 ± 0.03 5.96 ± 0.02 6.76 ± 0.04
A2AAR (L249V) 1.15 ± 0.15 8.17 ± 0.06 8.09 ± 0.03 6.92 ± 0.03 6.47 ± 0.07 7.17 ± 0.09
Figure 5.  Experimental (grey) and calculated (orange) relative changes in binding free energies to the  L249V6.51 
mutant  A2AAR for the two enantiomers of ISAM-140 and ZM241385.
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ISAM-140 enantiomers were separated and their absolute configuration unequivocally assigned. Besides this goal, 
the enantiomeric separation and pharmacological characterization of this reference  A2BAR antagonist allowed 
to confirm the expected higher affinity of the S enantiomer, in line with the original modeling  hypothesis11 and 
recent similar results obtained with derivatives of this  scaffold10,13,14.
Site-directed mutagenesis of position 6.51 was performed on the  A2AAR to replace the WT Leu by the Val 
specific of  A2BAR, as the reverse mutation of the  A2BAR appeared unfeasible in our hands, somehow in contrast 
to previous report of Müller and co-workers who managed to express the corresponding Ala mutant  (V250A6.51) 
in the  A2BAR23. It is worth noting that, while there had been reports of the Alanine scan of position 6.51 in both 
 A2A20 and  A2BARs23, this is the first time that the introduction of the  A2BAR characteristic Val sidechain on the 
 A2AAR is evaluated.
The  L249V6.51  A2AAR mutant partially recovered the affinity of ISAM-140 lost for this receptor, supporting 
the initial modeling hypothesis. This partial recovery in affinity, consistently observed for all three forms of this 
molecule (i.e., racemic mixture and both eutomers) is in line with recent reports on ‘selectivity hotspots’ between 
 A1AR and  A2AAR, where a single-point mutation clearly affecting the experimental binding mode could only 
partially explain the observed selectivity profile of the  A1AR selective xanthines under  investigation24. On the 
other hand, the opposed effect was observed for ZM241385 (i.e. decrease in affinity for the  L249V6.51  A2AAR 
mutant) in line with the well-described preference of this ligand for the  A2AAR.
To further assess the amino acid conservation between the  A2A and  A2BARs binding sites, a pseudo-sequence 
alignment is presented in Fig. 6. One can observe that, in addition to position 6.51 here studied, only two side-
chains vary within the 5 Å cut-off distance with the ligand:  Ala2536.54 in  A2BAR, situated one helix turn below 
Figure 6.  Pseudo-sequence alignment of the residues within 5 Å of any atom of (S)-ISAM140, as predicted by 
docking on the  A2BAR, between this receptor and the  A2AAR. The location of each sidechain is shown in the 3D 
superposition of the (S)-ISAM140-A2BAR (gray sidechains and cartoon, ligand in orange sticks) with the  A2AAR 
crystal structure (cyan sidechains). Position 6.51 is highlighted on a yellow box. Figure created with Pymol v2.0.
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position 6.51, is an Ile in  A2AAR. This residue, however, is not in contact with the ligand and instead involved in 
the TM packing as shown in the Fig. 6. In the EL3 region,  His2647.31 in  A2AAR is making a salt bridge interaction 
with  Glu1695.30 in EL2, a role that in our  A2BAR model is undertaken by  Lys2677.31 (Fig. 6). While this residue has 
been shown to be involved in ligand binding  kinetics1, we should not rule out an additional role of the more vari-
able EL regions in the selectivity profile of this antagonist. This analysis also allows to explore potential indirect 
effects of the  V6.51L mutation on neighbouring residues conserved in the ARs, like  His6.52 that has been shown 
to be involved in both agonist and antagonist  binding1. As it can be seen in Fig. 6., this residue is not predicted 
to change conformation between  A2A and  A2B ARs, which is supported by the water-mediated interaction with 
 Asn5.42 previously characterized by MD simulations of this pair of  receptors25.
In the lack of a crystal structure of the  A2BAR, the observed effects were rationalized back in the modeled 
structures, by means of first-principle FEP simulations of this mutation. The QresFEP protocol has been broadly 
applied to investigate the  A2AAR mutational  landscape26–28, showing exceptional sensitivity to capture the correct 
affinity shifts for different chemotypes. The binding model of (S)-ISAM-140 to the WT and  L249V6.51 mutant 
versions of  A2AAR was here assumed to be the same as our docking model of this compound to the WT  A2BAR13. 
That model suggested that the high  A2BAR affinity of ( ±) ISAM-140 was due to the stereoselective optimal fitting 
of the (S) isomer to the  A2BAR binding site, facilitated by the Val sidechain in position 6.51 of this  receptor13. The 
calculated recovery of the binding affinity of (S)-ISAM-140 upon the  L249V6.51 mutation in the  A2AAR, which 
is in line with the experimental design of this  A2B-like mutation on the  A2AAR, further confirms the validity of 
the binding model for this chemotype on the  A2BAR.
Overall, both experimental and computational results of this study clearly support the binding mode used 
to design this study, providing useful structural insights in the selective recognition of these  A2BAR antagonists 
that should aid in future structure-based optimization.
Methods
HPLC separation and characterization of ISAM‑140 enantiomers. The chiral resolution of the 
razemic ligand ISAM-140 was performed following procedures recently  described13. Briefly, chiral resolution 
was performed using a Water Breeze 2 (binary pump 1525, detector UV/Visible 2489, 7725i Manual Injec-
tor Kit 1500 Series). Compound ISAM-140 enantiomers were separated using a 250 mm × 20 mm Chiralpak 
5 µm IE-3 (DAICEL). All the separations were performed at 25 ºC with hexane/isopropanol 7:3 as mobile phase. 
The enantiomers [(R)-ISAM-140 (3 mg,  tR = 17.90 min), (S)-ISAM-140 (3.1 mg,  tR = 20.31 min)] were isolated, 
their stereochemical purity analyzed by chiral HPLC (ee: 97–99% for each enantiomer) and then characterized 
by NMR (see Supplementary Material).
Circular dichroism. Circular dichroism spectra were recorded on a Jasco-815 system equipped with a Pel-
tier-type thermostatic accessory (CDF-426S, Jasco). Measurements were carried out at 20  °C using a 1  mm 
quartz cell in a volume of 600 µL. Compounds (0.5 mg) were dissolved in MeOH (1.0 mL) and then diluted 
10-fld in MeOH. The instrument settings were bandwidth, 1.0 nm; data pitch, 1.0 nm; speed, 500 nm/min; accu-
mulation, 10; wavelengths, 400–190 nm.
X‑ray crystallography of ISAM‑140 enantiomers. Crystals of (S)-ISAM-140 and (R)-ISAM-140 were 
grown by slow evaporation from ethanol solutions. For the crystal structure  determination13, the data were col-
lected by applying the omega and phi scans method on a Bruker D8 VENTURE PHOTON III-14 diffractometer 
using Incoatec multilayer mirror monochromated with Cu-Kα radiation (λ = 1.54178  Å) from a microfocus 
sealed tube source at 100 K with detector resolution of 7.3910 pixels mm-1. Computing data and reduction were 
made with the APEX3 v2018.7–2 (BRUKER AXS, 2005). The structure was solved using SHELXT2018/22 and 
finally refined by full-matrix least-squares based on F2 by SHELXL2018/3.3 An empirical absorption correction 
was applied using the SADABS2016/2 program. Software used for molecular graphics: ORTEP for Windows. 
Software used to prepare material for publication: WinGX2018.3 publication routines4 and Mercury.
The obtained structures were refined following recently described methods as  follows13: All non-hydro-
gen atoms were refined anisotropically and the hydrogen atom positions were included in the model on the 
basis of Fourier difference electron density maps. All aromatic CH hydrogen (C-H = 0.95 Å), methine hydro-
gen (C-H = 1.0 Å) and methylene hydrogen (C-H = 0.99 Å) atoms were refined using a riding model with 
Uiso(H) = 1.2 Ueq(C). The methyl hydrogen (C–H = 0.98 Å) atoms were refined as a rigid group with torsional 
freedom [Uiso(H) = 1.5 Ueq(C)] and the hydrogens atom of NH groups (HiN) as a free atom with Uiso(H) = 1.2 
Ueq(C).
Site‑directed mutagenesis. Site-directed mutants of the  A2AAR were generated by polymerase chain 
reaction (PCR) mutagenesis as described  previously29. pcDNA3.1(+)-hA2AAR with N-terminal HA and FLAG 
tags and a C-terminal His tag was used as the template. Primers for mutants  L249V6.51 and  L249A6.51 were 
designed by the QuikChange Primer Design Program of Agilent Technologies (Santa Clara, CA, USA) and 
primers were obtained from Eurogentec (Maastricht, The Netherlands). All DNA sequences were verified by 
Sanger sequencing at LGTC (Leiden, The Netherlands).
Cell culture and transient transfection. CHO cells stably expressing the human  A2BAR (CHO-spap-
hA2BAR) were cultured in Dulbecco’s modified Eagle’s medium: Nutrient Mixture F-12 (DMEM/F12) supple-
mented with 10% newborn calf serum, 50 µg/mL streptomycin, and 50 IU/mL penicillin at 37 °C and 5%  CO2 
atmosphere. Cells were subcultured twice a week at a confluency of 80–90%. For transient transfections, human 
embryonic kidney (HEK) 293 cells were cultured as monolayers in DMEM supplemented with stable glutamine, 
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10% newborn calf serum, 50 µg/mL streptomycin, and 50 IU/mL penicillin at 37 °C and 7%  CO2 atmosphere 
as reported  previously29,30. The cells were seeded on 10 cm ø plates and transfected with 10 μg plasmid DNA 
of wild-type (WT) or mutant  hA2AAR using the calcium phosphate precipitation  method31, followed by a 48 h 
incubation.
Membrane preparation. HEK293 cells transiently expressing WT or mutant human  A2AAR (HEK293-
hA2AAR) were detached from the plates 48 h post-transfection by scraping into phosphate-buffered saline (PBS) 
and collected by centrifugation at 1,000 × g for 5 min. The pellets from 10 plates were pooled and resuspended in 
ice-cold Tris–HCl buffer (50 mM, pH 7.4) and then homogenized with an UltraTurrax homogenizer (Heidolph 
Instruments, Schwabach, Germany). The cell membrane suspensions were centrifuged at 100,000×g at 4 °C for 
20 min in a Beckman Optima LE-80 K ultracentrifuge. The pellet was resuspended in ice-cold Tris–HCl buffer, 
and the homogenization and centrifugation steps were repeated one more time. After this, Tris–HCl buffer was 
used to resuspend the pellet of HEK293 cell membranes. Membrane preparation for CHO-spap-hA2BAR cells 
followed a similar procedure after they were grown to 90% confluence in 15 cm plates, and membranes pellets 
were finally resuspended in Tris–HCL buffer containing 10% (w/v) CHAPS. In both cases, 0.8 IU/ml adenosine 
deaminase was added to break down endogenous adenosine and membranes were aliquoted into 250 μL and 
stored at -80 °C until further use. Membrane protein concentrations were determined using the BCA  method32.
Radioligand binding assays. Radioligand binding experiments on CHO-spap-hA2BAR membranes were 
adjusted from previously reported  data33. Membrane aliquots containing 30 µg of protein were incubated in a 
total volume of 100 µL of assay buffer. Nonspecific binding was determined with 10 µM ZM241385. Then 25 µL 
cell membrane suspension, 25 µL of 1.5 nM radioligand  [3H]PSB-603, 25 µL of assay buffer [50 mM Tris–HCl, 
0.1% (w/v) CHAPS, pH 7.4 at 25 °C] and 25 µL of the indicated compounds in increasing concentrations in the 
same assay buffer were added to each well and followed by a 120 min incubation at 25 °C. Radioligand displace-
ment experiments with transient HEK293-hA2AAR cell membranes were performed as described  previously34. 
Briefly, membrane aliquots containing 5–7.5 µg of protein were incubated in a total volume of 100 µL of assay 
buffer to adjust the assay window to approximately 2000 DPM. Nonspecific binding was determined in pres-
ence of 100 µM NECA and represented less than 10% of the total binding. Then 25 µL membrane suspension 
(5–7.5 µg of protein), 25 µL of 5.0 nM radioligand  [3H]ZM241385, 25 µL of assay buffer [50 mM Tris–HCl, pH 
7.4] and 25 µL of the indicated compounds at different concentrations in the same assay buffer were added to 
each well, with final assay concentration of radioligand of 5 nM. For homologous displacement experiments, 
radioligand displacement experiments were performed in presence of three concentrations of  [3H]ZM241385 
(1.7 nM, 5.0 nM and 9.5 nM) and increasing concentrations of unlabeled ZM241385. After 120 min at 25 °C, 
incubations were terminated by rapid vacuum filtration through GF/B filter plates (PerkinElmer, Groningen, 
Netherlands) using a Perkin Elmer Filtermate-harvester. Filterplates were subsequently washed ten times with 
ice-cold assay buffer. Filter-bound radioactivity was determined by scintillation spectrometry using a  Microbeta2 
2450 microplate counter (PerkinElmer).
Data analysis. Data analyses were performed using GraphPad Prism 7.0 software (GraphPad Software Inc., 
San Diego, CA).  pKD values and  Bmax were obtained by non-linear regression analysis using “one-site homolo-
gous” model.  pIC50 values were determined by fitting the data using non-linear regression to a sigmoidal con-
centration–response curve equation.  pKi values were calculated from  pIC50 values using the Cheng-Prusoff 
 equations35.
Computational modeling. The high resolution crystal structure of  A2AAR (PDB code  4EIY16) was used 
as a starting point for the calculations. The protein was prepared for MD simulations as follows: (i) removing 
co-factors and fused proteins employed for crystallization, (ii) reverting the crystal construct to the wild-type 
(WT)  A2AAR receptor, (iii) the assignment of protonation states of ionizable residues, (iv) mutation of the WT 
 Leu2496.51 to Val as in the corresponding  A2BAR and (v) membrane insertion using  PyMemDyn25. The latter 
stage involves embedding of the protein in a pre-equilibrated POPC membrane, soaking of the system with bulk 
water and a short (5 ns) equilibration period with GROMACS 4.636 using the OPLS-AA force  field37 and Berger 
parameters for the  lipids38. Thereafter, ligands were manually docked to the equilibrated receptor using as a 
reference the putative binding mode of  SYAF0147 to the  A2BAR previously described. In the case of ZM241385, 
the coordinates of the crystal structure ligand were retained during the equilibration process. Subsequently, each 
equilibrated  L249V6.51  A2AAR-ligand complex was transferred to the MD software  Q39 for free energy perturba-
tion (FEP) calculations under spherical boundary conditions using  QligFEP21. A 25 Å radius sphere centered 
on the center of geometry of the ligand was constructed for these MD simulations. Solvent atoms were subject 
to polarization and radial restraints using the surface-constrained all-atom solvent (SCAAS)40 model to mimic 
the properties of bulk water at the sphere surface. Atoms lying outside the simulation sphere were tightly con-
strained (200 kcal/mol/Å2 force constant) and excluded from the calculation of non-bonded interactions. Long 
range electrostatic interactions beyond a 10 Å cut off were treated with the local reaction field  method41, except 
for the atoms undergoing the FEP transformation, where no cutoff was applied. Solvent bond and angles were 
constrained using the SHAKE  algorithm42. All titratable residues outside the sphere were neutralized as reported 
 elsewhere21. Residue parameters were translated from the OPLS-AA/M force  field43 and the parameters for the 
lipids were inherited from the previous MD stage, while ligand parameters were generated using the ffld_server 
as implemented in the Schrödinger suite. The simulation sphere was warmed up from 0.1 to 298 K, during a 
first equilibration period of 0.61 ns, where an initial restraint of 25 kcal/mol/Å2 imposed on all heavy atoms was 
slowly released for all complexes. Thereafter the system was subject to 10 parallel replica MD simulations, in 
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which the FEP protocol was applied for each residue transformation. Each of these MD replicates started with a 
0.25 ns unbiased equilibration period, with different initial velocities. The FEP protocol for the L → V mutation 
was generated by combing the  QresFEP22 protocol for residue mutations with a dual topology approach inspired 
from  QligFEP21, where the effective topology along the transformation is a linear combination of the two origi-
nal sidechain topologies. Each FEP transformation consisted of 51 evenly distributed λ-windows with 10 ps MD 
sampling each. In order to fulfill a thermodynamic cycle and calculate relative binding free energies, parallel FEP 
transformations were run for the apo-structure, i.e. the protein structure without ligand. In these simulations 
the same parameters were applied (i.e., sphere size, simulation time, etc.), and a total of 10 replicates × 2 (apo/
holo) states × 2 (WT and mut) annihilations × 51 λ-windows × 10 ps = 20.4 ns sampling was performed for each 
mutation simulation. The relative binding free energy shift between WT and mutant receptors for each ligand 
was estimated by solving the thermodynamic cycle utilizing the Bennett acceptance ratio (BAR)44. All 3D images 
were produced in  PyMOL45.
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